SCHEMBL4092474

SCHEMBL4092474

Cc1ccc(C(=O)NC(CNC(=O)OCCl)C(C)C)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HPGD P15428 2/20 0.43
TAS1R3 Q7RTX0 2/20 0.41
TAS1R1 Q7RTX1 2/20 0.41
MAPT P10636 1/20 0.41
CCR3 P51677 5/20 0.40
TDP1 Q9NUW8 1/20 0.40
LMNA P02545 2/20 0.39
TP53 P04637 1/20 0.39
CTSS P25774 1/20 0.39
CTSK P43235 1/20 0.39
ADRB2 P07550 1/20 0.39
ADRB1 P08588 1/20 0.39
ADRB3 P13945 1/20 0.39
POLB P06746 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4088688 0.86 HPGD (0.46) KMT2AMEN1SMN1; SMN2HPGDTAS1R3
SCHEMBL4086683 0.84 SMN1; SMN2 (0.41) KMT2AMEN1SMN1; SMN2HPGDTAS1R3
SCHEMBL4092763 0.79 MLYCD (0.41) KMT2AMEN1SMN1; SMN2HPGDTAS1R3
SCHEMBL9937352 0.76 LMNA (0.53) KMT2AMEN1SMN1; SMN2HPGDTDP1
SCHEMBL13505507 0.76 LMNA (0.53) KMT2AMEN1SMN1; SMN2HPGDTDP1
SCHEMBL5661430 0.76 LMNA (0.41) KMT2AMEN1SMN1; SMN2TAS1R3TAS1R1
SCHEMBL5552111 0.76 LMNA (0.41) KMT2AMEN1SMN1; SMN2TAS1R3TAS1R1
SCHEMBL5552114 0.76 LMNA (0.41) KMT2AMEN1SMN1; SMN2TAS1R3TAS1R1
SCHEMBL5552121 0.76 LMNA (0.41) KMT2AMEN1SMN1; SMN2TAS1R3TAS1R1
SCHEMBL5662210 0.76 KMT2A (0.44) KMT2AMEN1SMN1; SMN2HPGDTAS1R3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023667-A1 Composition For Preventing Harmful Organisms MITSUI CHEMICALS, INC. (JP) 2009-01-22 US disclosed
EP-1872658-A1 PESTICIDAL COMPOSITION Mitsui Chemicals, Inc. (JP) 2008-01-02 EP disclosed
US-20070049635-A1 Diamine derivatives, process for producing the same, and plant disease control agents containing the same as active ingredients MITSUI CHEMICALS, INC. (JP) 2007-03-01 US disclosed
EP-1681285-A1 DIAMINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND PLANT DISEASE CONTROL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT Mitsui Chemicals, Inc. (JP) 2006-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049635-A1 Diamine derivatives, process for producing the same, and plant disease control agents containing the same as active ingredients HRH4, HRH1, DDT KMT2A 435/4885MEN1 1873/4885SMN1; SMN2 3370/4885
US-20090023667-A1 Composition For Preventing Harmful Organisms DDT, CBR3, AHR KMT2A 1247/4885MEN1 2918/4885SMN1; SMN2 3028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.